Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Channel Therapeutics Corporation (NYSE:CHRO) on Thursday signed a ...

Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused ...

Stifel initiated coverage of Ligand (LGND) with a Buy rating and $143 price target Ligand, which provides “an important source of ...

Ligand earns Buy rating from Stifel for its royalty-based funding model and biotech partnerships amid strong revenue and earnings growth.

Fintel reports that on April 10, 2025, Stifel initiated coverage of Ligand Pharmaceuticals Incorporated - Equity Right (OTCPK ...

Ligand Pharmaceuticals has struck a deal to combine its Pelthos Therapeutics unit with Channel Therapeutics in a bid to accelerate the commercialization of its Zelsuvmi treatment for molluscum ...